Puma Biotechnology presents positive PB272 clinical data at ASCO

theflyonthewall.com

Puma Biotechnology announced that results from an ongoing Phase I clinical trial of its lead drug candidate PB272 (neratinib) given in combination with the anticancer drugs paclitaxel and trastuzumab in patients with metastatic HER-2 positive breast cancer were presented in a poster presentation at the American Society of Clinical Oncology, ASCO, 2012 Annual Meeting. This trial was sponsored by the National Surgical Adjuvant Breast and Bowel Project, NSABP, a clinical trials cooperative group supported by the National Cancer Institute,NCI.

View Comments